Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Upgraded by Wall Street Zen

Werewolf Therapeutics (NASDAQ:HOWL) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings lowered Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $4.00.

Werewolf Therapeutics Price Performance

HOWL opened at $0.87 on Friday. The stock has a market cap of $42.45 million, a PE ratio of -1.15 and a beta of 0.29. The business has a 50 day moving average of $0.39 and a 200-day moving average of $0.58. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Friday, July 31st. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.36. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $21.00 million. Equities analysts anticipate that Werewolf Therapeutics will post -1.08 EPS for the current year.

Insider Buying and Selling

In other news, Director Luke Evnin sold 107,429 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $0.31, for a total value of $33,302.99. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the sale, the insider owned 303,719 shares in the company, valued at $106,301.65. The trade was a 57.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,218,524 shares of company stock valued at $851,252 in the last ninety days. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its holdings in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after acquiring an additional 25,882 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after acquiring an additional 221,766 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Werewolf Therapeutics during the second quarter valued at $409,000. Finally, Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics in the 3rd quarter worth about $304,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Key Werewolf Therapeutics News

Here are the key news stories impacting Werewolf Therapeutics this week:

• Positive Sentiment: The proposed merger would bring a Phase 3 asset into the combined company. Neridronate is being evaluated in the ongoing CRPS-RISE trial and could become the first FDA-approved drug specifically for CRPS-1, a debilitating condition affecting approximately 65,000 newly diagnosed U.S. patients annually. The drug has received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations. Werewolf and Ambros Therapeutics announce merger
• Positive Sentiment: The oversubscribed $150 million financing, backed by healthcare investors including RA Capital Management and Janus Henderson Investors, is expected to fund operations through CRPS-RISE topline results anticipated in 2028 and a potential FDA filing, with cash runway projected into the first half of 2029. Merger agreement and private placement
• Neutral Sentiment: The transaction is expected to close by the first quarter of 2027, subject to shareholder approvals, SEC registration and other customary conditions. After closing, the company is expected to operate as Ambros Therapeutics and trade under the ticker AMBX. Werewolf Therapeutics to merge with Ambros Therapeutics
• Negative Sentiment: The deal substantially dilutes existing HOWL holders: pre-merger Werewolf stockholders are expected to own approximately 6.8% of the combined company, while Ambros shareholders would own about 71.7% and financing investors 21.5%. The implied transaction value for Werewolf is $47.5 million versus $500 million for Ambros.
• Negative Sentiment: Investors still face clinical, regulatory and closing risks. Neridronate must produce positive Phase 3 results, and the FDA could require additional data or trials; the financing and merger could also be delayed or fail to close.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.